By 2024, routine testing for genomic alterations has expanded to nine genes with matched targeted therapies for advanced non–small-cell lung cancer (NSCLC) — EGFR, ALK, ROS1, RET, MET, KRAS, NTRK, BRAF, and ERBB2. More than half of patients with NSCLC have genomic alterations in tumor...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be determined. This study compares the effi...
Osimertinib is an irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is the preferred first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) compared to first-generation EGFR-TKIs.
In summary, the rapid development of EGFR-TKIs has revolutionized the treatment patterns of EGFR-mutated NSCLC, which improved the survival and quality of life of this population. Nevertheless, similar to early-generation EGFR-TKIs, intractable matters of acquired resistance to osimertinib also inevitab...
Revealing the graphical abstract of the entire study reporting dodecagonal strategy for EGFR-mutated NSCLC. Full size image Results of the dodecagonal strategy The results of this study are based on a stringent computational pathway that involves six complexes: 2ITU-CUR, 2ITV-CUR, 2ITX-CUR, ...
EGFR-mutated NSCLC is minimally responsive to programmed cell death protein 1 or programmed death-ligand 1 blockade. We evaluated the safety, tolerability, and immunomodulatory effects of the EGFR tyrosine kinase inhibitor (TKI) afatinib in combination with the programmed cell death protein 1 antibody...
Background Osimertinib is a key-drug to treat NSCLC harboring EGFR sensitizing mutation at 1st line setting as well as T790M resistant mutation at late line. Interstitial lung disease/pneumonitis (ILD) is a fatal adverse event induced by tyrosine kinase inhibitors including osimertinib especially in ...
progression of tumors in 60% of NSCLC may be attributed to the overexpression of VEGF [89,90,91]. Another factor that motivates the exploration of EGFR as a possible target in cancer and angiogenesis is associated with the fact that, while this receptor is predominantly not present in ...
However, there is no consensus on the optimal therapy for patients with osimertinib-resistant EGFR-mutated NSCLC harboring a BRAF V600E mutation. Here, we present the case of the oldest patient treated with a combination of osimertinib, dabrafenib, and trametinib. In an 81-year-old woman, ...
In November 2023,Johnson & Johnsonsubmitteda supplemental Biologics License Application (sBLA) to the U.S. FDA for RYBREVANT®in combination with chemotherapy for the treatment of patients withEGFR-mutated NSCLC who ...